Accelerated Approval is based on Phase 2 data showing a reduction in amyloid-beta plaques in early AD patients treated with LEQEMBI™ Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials TOKYO and CAMBRIDGE, Mass., Jan. 6, …
TOKYO, Jan. 6, 2023 /PRNewswire/ — LEQEMBI™ (lecanemab-rimb) has the potential to make a difference for people living with early Alzheimer’s disease (AD), their loved ones and healthcare professionals, and was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of AD. Eisai has worked with the FDA and the FDA has approved …
EISAI’S COMMITMENT TO SCIENTIFIC EVIDENCE AND PATIENT Read More »
Multiple Sclerosis is a long-term illness where the body’s immune system attacks and damages the protective covering, called myelin, around the nerves in the central nervous system. People with relapsing MS will have repeated attacks, known as relapses, and we’re finding new ways to stop them. People with MS can experience a variety of symptoms, …
WE’RE FINDING NEW WAYS TO TREAT MULTIPLE SCLEROSIS Read More »
Alzheimer’s disease is the most frequent cause of dementia in Western societies. In the US, approximately 6.5 million people are affected, and the prevalence worldwide is estimated to be as high as 50 million. As the population continues to age, the number of individuals at risk will also increase. Alzheimer’s disease is the leading cause …
THERE IS HOPE IN TREATING ALZHEIMER’S DISEASE AND ONE DAY, FINDING A CURE Read More »
A clinical research trial is led by an experienced medical staff that tests a study drug or medical device in volunteers who are participating in a study. These tests are used to see if the study drug or device is safe and effective for people to use. Each clinical trial follows a protocol, which sets …
WHAT ARE THE BENEFITS OF CLINICAL RESEARCH TRIALS AND WHY DO WE NEED THEM? Read More »
Multiple Sclerosis is a long-term illness where the body’s immune system attacks and damages the protective covering, called myelin, around the nerves in the central nervous system. People with relapsing MS will have repeated attacks, known as relapses, and we’re finding new ways to stop them. People with MS can experience a variety of symptoms, …
CuraSen Therapeutics, Inc. is a privately funded biopharmaceutical company pursuing development of novel treatments for neurodegenerative diseases, including Alzheimer’s and Parkinson’s disease. Some of the earliest signs of neurodegeneration (inflammation, proteinopathy and neuronal atrophy), including that seen in Alzheimer’s and Parkinson’s diseases, occur in the locus coeruleus (LC, literally ‘blue place’) named for the bluish …
AN ALL NEW APPROACH TO STOP DISEASE PROGRESSION IN ALZHEIMER’S AND PARKINSON’S DISEASE Read More »
Since 1992, Bradenton Research Center has completed over 150 clinical research studies. The diseases we’ve studied include Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Influenza, Migraines, Neuropathic Pain, Gout, Hypertension, Stroke, Type 2 Diabetes, Diabetic Neuropathy, Epilepsy, COVID-19, and many others. Led by Medical Director Eric Folkens, MD, our research team has more than 30 years of …
LEARN MORE ABOUT GETTING INVOLVED IN CLINICAL RESEARCH TRIALS Read More »
Learn more about getting involved in clinical trials. Receive compensation and free medical care, while helping with the advancements of medical research. For researchers who conduct clinical trials, enrolling enough patients to make a trial meaningful is always a challenge. Enrolling a single patient in a study often requires not one but two participants, the …
NEW MEDICAL ADVANCEMENT FOR TREATING ALZHEIMER’S AND PARKINSON’S DISEASE Read More »
Clinical trials are medical research studies involving patients. They can help discover new medicines, or get improved versions of existing medicines. The main objective of a clinical research study is to answer questions about the safety and effectiveness of these potential new medications. These studies must be completed before a new treatment can be offered …
WHAT WOULD MEDICINE BE LIKE WITHOUT THE CLINICAL TRIALS WE HAVE TODAY? Read More »
Copyright © 2023 Bradenton Research Center | Website Designed by Rohring Results
